文献速递免疫规划卫生政策与健康促进

美国假设性COVID-19疫苗的公共卫生与经济价值:成本效果模型辅助疫苗优先接种

The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
PubMed 文献 · Vaccine · 2021-01-06

研究采用Markov队列模型评估美国假设性60%效力COVID-19疫苗的价值。结果显示,全美成年人群每获得一个QALY的增量成本为8200美元,65岁及以上人群接种可节省成本;在最优供应情景下疫苗可预防31%的预期死亡。

要点

  • 全美成年人群接种假设性疫苗的每QALY增量成本为8200美元,具有成本效果。
  • 65岁及以上人群接种相比不接种可节省成本。
  • 低住院和死亡风险人群每QALY成本增至超过94000美元。

核心结论

  • 假设性COVID-19疫苗在美国成年人群中每获得一个QALY的增量成本为8200美元,低于50000美元阈值,具有良好成本效果。
  • 对65岁及以上等高并发症风险人群接种可节省成本。

研究设计与样本

  • 采用Markov队列模型,比较接种与不接种60%效力疫苗的美国成年人群,并设定三种优先接种分层方案。

主要发现

  • 全美成年人群每QALY增量成本为8200美元。
  • 65岁及以上人群接种可节省成本。
  • 低住院和死亡风险人群每QALY成本超过94000美元。
  • 最优供应情景下疫苗可预防31%的预期死亡,供应更受限时仅预防23%。

关键数值与推荐

  • 假设疫苗效力为60%。
  • 全美成年人群每QALY增量成本为8200美元。
  • 65岁及以上人群接种可节省成本。
  • 低风险人群每QALY成本超过94000美元。
  • 最优供应情景下预防31%的预期死亡,供应受限时预防23%。

临床怎么用

  • 在疫苗供应受限时,优先为65岁及以上等高并发症风险人群接种可最大化健康收益并节省成本。
  • 低风险人群接种的成本效果较差,每QALY成本超过94000美元。

局限性

  • 结果对感染发病率、疫苗价格、COVID-19治疗成本和疫苗效力最为敏感。
  • 模型基于假设性疫苗和特定参数,实际价值取决于真实疫苗特征与疫情动态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Researchers are working at unprecedented speed to develop a SARS-CoV-2 vaccine. We aimed to assess the value of a hypothetical vaccine and its potential public health impact when prioritization is required due to supply constraints. METHODS: A Markov cohort model was used to estimate COVID-19 related direct medical costs and deaths in the United States (US), with and without implementation of a 60% efficacious vaccine. To prioritize the vaccine under constrained supply, the population was divided into tiers based on age; risk and age; and occupation and age; and outcomes were compared across one year under various supply assumptions. The incremental cost per quality-adjusted life-year (QALY) gained versus no vaccine was calculated for the entire adult population and for each tier in the three prioritization schemes. RESULTS: The incremental cost per QALY gained for the US adult population was $8,200 versus no vaccination. For the tiers at highest risk of complications from COVID-19, such as those ages 65 years and older, vaccination was cost-saving compared to no vaccination. The cost per QALY gained increased to over $94,000 for those with a low risk of hospitalization and death following infection. Results were most sensitive to infection incidence, vaccine price, the cost of treating COVID-19, and vaccine efficacy. Under the most optimistic supply scenario, the hypothetical vaccine may prevent 31% of expected deaths. As supply becomes more constrained, only 23% of deaths may be prevented. In lower supply scenarios, prioritization becomes more important to maximize the number of deaths prevented. CONCLUSIONS: A COVID-19 vaccine is predicted to be good value for money (cost per QALY gained <$50,000). The speed at which an effective vaccine can be made available will determine how much morbidity and mortality may be prevented in the US.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kohli M, Maschio M, Becker D, et al. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021. PMID: 33483216. doi:10.1016/j.vaccine.2020.12.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。